Literature DB >> 6553511

Immunomodulating activity of thymosin fraction 5 and thymosin alpha 1 in immunosuppressed mice.

Y Ohta, K Sueki, Y Yoneyama, E Tezuka, Y Yagi.   

Abstract

We found that both thymosin from calf thymus and its constituent peptide alpha 1 prepared by chemical synthesis restore cell-mediated immunity following its suppression in mice by injection of 5-FU. Conditions suitable for assessing the thymosin activity by means of footpad reaction were established in such immunosuppressed mice. In this new animal model, thymosin alpha 1-peptide showed activity at a low dose of 5-50 micrograms/kg, which was 100-1,000 times less than that required for thymosin F-5 preparations. Further studies utilizing the adoptive transfer technique showed that alpha 1-peptide corrects the 5-FU-induced suppression of mature T cells, transferring the DTH response as well as that of macrophage function responsible for the expression of footpad reaction. Furthermore, regeneration of lymph node and bone marrow cells as well as CFU-c (progenitor cells of macrophages and granulocytes) was enhanced by thymosin alpha 1 in the 5-FU-treated mice. All these results indicate that thymosin alpha 1 accelerates the replenishment and maturation of haematopoietic cells, including not only T cells but also macrophages, when they have been severely damaged by the 5-FU treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6553511     DOI: 10.1007/bf00199700

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  Immunological reconstitution of T-cell-deprived mice. I. Inability of thymosin to restore spleen cell mitogen and tumor allograft response.

Authors:  F J Primus; L De Martino; R MacDonald; H J Hansen
Journal:  Cell Immunol       Date:  1978-01       Impact factor: 4.868

2.  Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human.

Authors:  J F Bach; M Dardenne; J M Pleau; M A Bach
Journal:  Ann N Y Acad Sci       Date:  1975-02-28       Impact factor: 5.691

3.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

4.  Purification and biological activity of thymosin, a hormone of the thymus gland.

Authors:  A L Goldstein; A Guha; M M Zatz; M A Hardy; A White
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

5.  Acceleration of lymphoid tissue regeneration in x-irradiated CBA-W mice by injection of thymosin.

Authors:  A L Goldstein; S Banerjee; G L Schneebeli; T F Doughtery; A White
Journal:  Radiat Res       Date:  1970-03       Impact factor: 2.841

6.  Effect of thymosin in vitro on T cell levels during radiation therapy: correlations with radiation portal and initial T cell levels.

Authors:  D E Kenady; P B Chretien; C Potvin; R M Simon; J C Alexander; A L Goldstein
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

7.  Thymosin activity in patients with cellular immunodeficiency.

Authors:  D W Wara; A L Goldstein; N E Doyle; A J Ammann
Journal:  N Engl J Med       Date:  1975-01-09       Impact factor: 91.245

8.  Protective activity of thymosin against opportunistic infections in animal models.

Authors:  H Ishitsuka; Y Umeda; J Nakamura; Y Yagi
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil.

Authors:  Y Ohta; K Sueki; K Kitta; K Takemoto; H Ishitsuka; Y Yagi
Journal:  Gan       Date:  1980-04

10.  Studies on some physicochemical properties of a thymus humoral factor conferring immunocompetence on lymphoid cells.

Authors:  N Trainin; M Small
Journal:  J Exp Med       Date:  1970-11       Impact factor: 14.307

View more
  6 in total

1.  Thymic factor-induced reduction of pulmonary metastases in mice with FSA-1 fibrosarcoma.

Authors:  V J Tomazic; C R Sacasa; A Loftus; C S Suter; G E Elias
Journal:  Clin Exp Metastasis       Date:  1988 Jan-Feb       Impact factor: 5.150

2.  A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Robert G Gish; Stuart C Gordon; David Nelson; Vinod Rustgi; Israel Rios
Journal:  Hepatol Int       Date:  2009-05-08       Impact factor: 6.047

3.  Modulation of natural killer activity by thymosin alpha 1 and interferon.

Authors:  C Favalli; T Jezzi; A Mastino; C Rinaldi-Garaci; C Riccardi; E Garaci
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Enhancement of natural killer cell activity in mice by treatment with a thymic factor.

Authors:  F Bistoni; M Baccarini; P Puccetti; P Marconi; E Garaci
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Thymosin α1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK.

Authors:  Walter Mandaliti; Ridvan Nepravishta; Francesca Pica; Paola Sinibaldi Vallebona; Enrico Garaci; Maurizio Paci
Journal:  Molecules       Date:  2017-10-27       Impact factor: 4.411

Review 6.  The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy.

Authors:  Hong-Yuan Lin
Journal:  Chin J Traumatol       Date:  2020-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.